Novartis collaborating with Intel to help accelerate early-stage drug discovery using deep neural networks

June 05, 2018 | Case Study

Novartis is one of the world's largest pharmaceutical companies, with more than $50 billion in revenues, and as a firm has had a recent leadership transition, with new CEO Vas Narasimhan recently taking the helm. The new CEO has emphasized digital transformation and artificial intelligence, including a push to look for partnerships and acquisitions around drug discovery and development. Indeed, during the past few years the company has made some initial forays in this direction, including working with IBM's Watson arm around advanced breast cancer treatment and tapping McKinsey's QuantumBlack unit for work on clinical trial analysis. In parallel to these external collaborations, however, Novartis is also looking at how it can tap external vendors to improve the internal efficiency of its R&D staff and the experiments that they run around drug discovery.